AstraZeneca Results Presentation Deck
Total Revenue ($m)
5,000
4,500
4,000
Oncology - 9M and Q3 2023
Total Revenue +20% in 9M 2023 fueled by strong global demand growth
3,500
3,000
2,500
2,000
1,500
1,000
500
0
Q3
2021
Q4
Oncology
9M 2023 $13.5bn, +20%
Q1 Q2
I
2022
Q3 Q4
Q1
Q2
2023
Q3
CEO Opening Remarks
Tagrisso Imfinzi/Imjudo Calquence Enhertu Lynparza (PS) Lynparza milestones Others
●
●
●
●
Financial Results
●
Oncology
●
BioPharmaceuticals
Rare Disease
Q3 2023: key dynamics
Imfinzi/Imjudo +54%, continued strong global launch momentum
Calquence +15%, preferred BTKi across 1L and r/r CLL
• Enhertu +86%, penetration in DB03, DB04 and new global
launches uptake ex-US
CEO Closing Remarks
Tagrisso +6%, continued ADAURA and FLAURA global demand
growth, short-term impact from anti-corruption campaign in CN
Lynparza PS +8%, EU, EROW, EM demand growth slightly offset by
2L OC label restriction, decreased PARPI use in the US
New indications: EU, JP (Enhertu DL02), CN (Calquence CLL/SLL)
Regulatory update: US (Tagrisso FLAURA2 Priority Review,
Imfinzi AEGEAN submission acceptance)
All growth rates at CER.
15
CER= constant exchange rates; NRDL = National Reimbursement Drug List; PS = Product Sales; EU = Europe; EROW= Established Rest of World; EM = Emerging Markets; CN = China; 2L = 2nd-line; OC = ovarian cancer; PARPi = poly
(ADP-ribose) polymerase inhibitor; BTKi = bruton tyrosine kinase inhibitor; 1L = 1st-line; r/r CLL = relapsed/refractory chronic lymphocytic leukaemia; DB03 = DESTINY-Breast03; DB04 = DESTINY-Breast04; DL02= DESTINY-Lung02; SLL
= small lymphocytic lymphoma.
Collaboration partners: Daiichi Sankyo (Enhertu), Merck & Co., Inc. (Lynparza).View entire presentation